Display options
Cite
Tapaskar N, Colon Hidalgo D, Koo G, et al. Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study. Ann Pharmacother. 2021;10600280211021925doi: 10.1177/10600280211021925.
Tapaskar, N., Colon Hidalgo, D., Koo, G., Shingada, K., Rao, S., Rodriguez, R., Alcantar, D., Espinoza Barrera, D., Lee, R., Rameshkumar, N., Amine, M., Rodrigues, S., Giron, F., Chaugule, A., & Rech, M. A. (2021). Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study. The Annals of pharmacotherapy, 10600280211021925. https://doi.org/10.1177/10600280211021925
Tapaskar, Natalie, et al. "Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study." The Annals of pharmacotherapy vol. (2021): 10600280211021925. doi: https://doi.org/10.1177/10600280211021925
Tapaskar N, Colon Hidalgo D, Koo G, Shingada K, Rao S, Rodriguez R, Alcantar D, Espinoza Barrera D, Lee R, Rameshkumar N, Amine M, Rodrigues S, Giron F, Chaugule A, Rech MA. Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study. Ann Pharmacother. 2021 Jun 02;10600280211021925. doi: 10.1177/10600280211021925. Epub 2021 Jun 02. PMID: 34075807.
Copy Download .nbib Format: NLM
Share it on

Ann Pharmacother. 2021 Jun 02;10600280211021925. doi: 10.1177/10600280211021925. Epub 2021 Jun 02.

Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study.

The Annals of pharmacotherapy

Natalie Tapaskar, Daniel Colon Hidalgo, Grace Koo, Krupa Shingada, Swathi Rao, Raul Rodriguez, Daniel Alcantar, Diana Espinoza Barrera, Raymond Lee, Naveen Rameshkumar, Mukarram Amine, Shelden Rodrigues, Fanny Giron, Akshata Chaugule, Megan A Rech

Affiliations

  1. Stanford University Medical Center, Stanford, CA, USA.
  2. University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  3. Vanderbilt University Medical Center, Nashville, TN, USA.
  4. Loyola University Medical Center MacNeal Hospital, Berwyn, IL, USA.
  5. Loyola University Chicago, Maywood, IL, USA.
  6. Loyola University Medical Center, Maywood, IL, USA.

PMID: 34075807 DOI: 10.1177/10600280211021925

Abstract

BACKGROUND: Patients with COVID-19 acute respiratory distress syndrome (ARDS) have been shown to have high sedation requirements.

OBJECTIVE: The purpose of this study was to compare sedative use between patients with COVID-19 ARDS and non-COVID-19 ARDS.

METHODS: This was a retrospective study of patients with COVID-19 ARDS compared with historical controls of non-COVID-19 ARDS who were admitted to 2 hospitals from March 1, 2020, to April 30, 2020, and April 1, 2018, to December 31, 2019, respectively. The primary outcome was median cumulative dose of propofol (µg/kg) at 24 hours after intubation.

RESULTS: There were 92 patients with COVID-19 ARDS and 37 patients with non-COVID-19 ARDS included. Within the first 24 hours of intubation, patients with COVID-19 ARDS required higher total median doses of propofol: 51 045 µg/kg (interquartile range, 26 150-62 365 µg/kg) versus 33 350 µg/kg (9632-51 455 µg/kg;

CONCLUSION AND RELEVANCE: Patients with COVID-19 ARDS required higher doses of propofol and benzodiazepines than patients with non-COVID-19 ARDS to achieve the same median levels of sedation.

Keywords: ARDS; COVID-19; analgesia; sedation

Publication Types